scholarly journals Emotional experience is increased and emotion recognition decreased in multiple sclerosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Line Pfaff ◽  
Daniel Gounot ◽  
Jean-Baptiste Chanson ◽  
Jérôme de Seze ◽  
Frédéric Blanc
Keyword(s):  
Multiple Sclerosis ◽  
Emotion Recognition ◽  
Emotional Disorders ◽  
Facial Expressions ◽  
Emotional Experience ◽  
International Affective Picture System ◽  
Control Group ◽  
Healthy Controls ◽  
Subjective Evaluations ◽  
Emotional Dimensions

AbstractEmotional disorders in multiple sclerosis (MS) are frequently described as difficulties in recognizing facial expressions, rarely in the experience dimension. Moreover, interaction between emotional disorders and cognitive or psychological disorders remains little documented. The aim of this study is to explore emotions in MS in emotion recognition and emotional experience and compare these data with cognitive, psychological, and disease aspects. Twenty-five women with MS (MS group) and 27 healthy controls (control group) matched for age, sex, and education were assessed for emotion recognition (Florida Affect Battery) and emotional experience (International Affective Picture System Photographs). Participants were also assessed for cognitive and psychological aspects. Compared to the control group, the MS group had more difficulty in recognizing emotions, and their subjective evaluations when presented IAPS pictures were more scattered, globally increased. Emotional dimensions were each correlated with executive functions but neither correlated with alexithymia, depression, anxiety, or MS characteristics. In conclusion, MS patients present difficulties in identifying emotion and their emotional experience appears to be increased. These disorders are correlated with cognition but remain independent of psychological or disease aspects. Considering the implications that emotional disorders may have, it seems essential to take these aspects into account in clinical practice.

Association between circulating leptin levels and multiple sclerosis: a systematic review and meta-analysis

2018 ◽  
Vol 94 (1111) ◽  
pp. 278-283 ◽  
Author(s):  
Xue-Feng Xie ◽  
Xiao-Hui Huang ◽  
Ai-Zong Shen ◽  
Jun Li ◽  
Ye-Huan Sun
Keyword(s):  
Multiple Sclerosis ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Control Group ◽  
Sample Type ◽  
Healthy Controls ◽  
Eligibility Criteria ◽  
Effect Model ◽  
Healthy Control

AimLeptin, synthesised by adipocytes, has been identified as a hormone that can influence inflammatory activity. Several studies have investigated leptin levels in patients with multiple sclerosis (MS), but the results are not consistent. This study aims to derive a more precise evaluation on the relationship between circulating leptin levels and MS.DesignA comprehensive literature searched up to July 2017 was conducted to evaluate the association of circulating leptin levels and MS. The random-effect model was applied to calculate pooled standardised mean difference (SMD) and its 95% CI.Main outcome measuresCirculating leptin levels of patients with MS and healthy controls.ResultsOf 2155 studies identified, 33 met eligibility criteria and 9 studies with 645 patients with MS and 586 controls were finally included in the meta-analysis. Meta-analysis revealed that, compared with the healthy control group, the MS group had significantly higher plasma/serum leptin levels, with the SMD of 0.70% and 95% CI (0.24 to 1.15). Subgroup analyses suggested that the leptin levels of patients with MS were associated with region, age, study sample size, measurement type, gender and blood sample type.ConclusionOverall, our study suggests that patients with MS have a significantly higher leptin level than in healthy controls. Further mechanism studies and longitudinal large cohort studies are still needed to further reveal the role of leptin in the pathogenesis of MS.

scholarly journals Transdiagnostic treatment of emotional disorders in people with multiple sclerosis: randomized controlled trial

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Nabi Nazari ◽  
Masood Sadeghi ◽  
Ezatolah Ghadampour ◽  
Davod Mirzaeefar
Keyword(s):  
Multiple Sclerosis ◽  
Emotional Disorders ◽  
Analysis Of Covariance ◽  
High Rate ◽  
Control Group ◽  
Depression Symptoms ◽  
Usual Condition ◽  
Transdiagnostic Treatment ◽  
Assessment Protocol ◽  
Unified Protocol

Abstract Background Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system. MS is significantly associated with a high rate of psychological, behavioral, and emotional consequences. Despite the frequent mental disorders, high rate of psychological comorbidities, and emotional problems in people with MS (PwMS), these conditions are often underdiagnosed and undertreated. This study aimed to examine the efficacy of a group format of the unified protocol for the transdiagnostic treatment of emotional disorders in adult PwMS associated with an emotional disorder. Methods Seventy adult PwMS were randomized using an internet-based computer system to either the unified protocol (n = 35) or treatment as usual condition. The assessment protocol included semi-structured clinical interviews and self-reports evaluating diagnostic criteria, depression, anxiety and worry symptoms, emotional dysregulation, and affectivity. Results The parametric test of analysis of covariance, followed the intent to treat analyses, revealed the unified protocol significantly changed depression symptoms (Cohen’s d = 1.9), anxiety symptoms (Cohen’s d = 2.16), worry symptoms (Cohen’s d = 1.27), emotion dysregulation (Cohen’s d = 0.44), positive affect (Cohen’s d = 1.51), and negative affect (Cohen’s d = 1.89) compared with the control group. The unified protocol also significantly improved outcome scores at the end of treatment relative to baseline (p < .001). Conclusion The findings support that the unified protocol could be an additional efficient psychological treatment for PwMS. Trial registration IRCT, number: IRCT20190711044173N1. Registered 31october 2019, https://en.irct.ir/user/trial/40779/view.

scholarly journals Changes in Amino Acid and Acylcarnitine Plasma Profiles for Distinguishing Patients with Multiple Sclerosis from Healthy Controls

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Marat F. Kasakin ◽  
Artem D. Rogachev ◽  
Elena V. Predtechenskaya ◽  
Vladimir J. Zaigraev ◽  
Vladimir V. Koval ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Amino Acid ◽  
Discriminant Analysis ◽  
Clinical Decision ◽  
Partial Least Square ◽  
Least Square ◽  
Control Group ◽  
Healthy Controls ◽  
Linear Discriminant ◽  
Tandem Mass Spectrometric

McDonald criteria and magnetic resonance imaging (MRI) are used for the diagnosis of multiple sclerosis (MS); nevertheless, it takes a considerable amount of time to make a clinical decision. Amino acid and fatty acid metabolic pathways are disturbed in MS, and this information could be useful for diagnosis. The aim of our study was to find changes in amino acid and acylcarnitine plasma profiles for distinguishing patients with multiple sclerosis from healthy controls. We have applied a targeted metabolomics approach based on tandem mass-spectrometric analysis of amino acids and acylcarnitines in dried plasma spots followed by multivariate statistical analysis for discovery of differences between MS (n=16) and control (n=12) groups. It was found that partial least square discriminant analysis yielded better group classification as compared to principal component linear discriminant analysis and the random forest algorithm. All the three models detected noticeable changes in the amino acid and acylcarnitine profiles in the MS group relative to the control group. Our results hold promise for further development of the clinical decision support system.

scholarly journals Student Prize-Winning Abstracts 2010

2011 ◽  
Vol 12 (1) ◽  
pp. 77-77
Author(s):  
Sharpley Hsieh ◽  
Olivier Piguet ◽  
John R. Hodges
Keyword(s):  
Emotion Recognition ◽  
Facial Expressions ◽  
Negative Emotions ◽  
Emotion Detection ◽  
Recognition Of Facial Expressions ◽  
Patient Groups ◽  
The Neural Networks ◽  
Emotional Dimensions ◽  
Recognition Of Emotions ◽  
Valence And Arousal

AbstractIntroduction: Frontotemporal dementia (FTD) is a progressive neurode-generative brain disease characterised clinically by abnormalities in behaviour, cognition and language. Two subgroups, behavioural-variant FTD (bvFTD) and semantic dementia (SD), also show impaired emotion recognition particularly for negative emotions. This deficit has been demonstrated using visual stimuli such as facial expressions. Whether recognition of emotions conveyed through other modalities — for example, music — is also impaired has not been investigated. Methods: Patients with bvFTD, SD and Alzheimer's disease (AD), as well as healthy age-matched controls, labeled tunes according to the emotion conveyed (happy, sad, peaceful or scary). In addition, each tune was also rated along two orthogonal emotional dimensions: valence (pleasant/unpleasant) and arousal (stimulating/relaxing). Participants also undertook a facial emotion recognition test and other cognitive tests. Integrity of basic music detection (tone, tempo) was also examined. Results: Patient groups were matched for disease severity. Overall, patients did not differ from controls with regard to basic music processing or for the recognition of facial expressions. Ratings of valence and arousal were similar across groups. In contrast, SD patients were selectively impaired at recognising music conveying negative emotions (sad and scary). Patients with bvFTD did not differ from controls. Conclusion: Recognition of emotions in music appears to be selectively affected in some FTD subgroups more than others, a disturbance of emotion detection which appears to be modality specific. This finding suggests dissociation in the neural networks necessary for the processing of emotions depending on modality.

Facial Affect Recognition in Myasthenia Gravis

2013 ◽  
Vol 16 ◽  
Author(s):  
Esther Lázaro ◽  
Imanol Amayra ◽  
Juan Francisco López-Paz ◽  
Amaia Jometón ◽  
Natalia Martín ◽  
...  
Keyword(s):  
Reaction Time ◽  
Emotion Recognition ◽  
Facial Expressions ◽  
Recognition Accuracy ◽  
Facial Affect ◽  
Facial Emotion Recognition ◽  
Facial Emotion ◽  
Healthy Controls ◽  
Emotional Facial Expressions ◽  
Clinical Neurological Examination

AbstractThe assessment of facial expression is an important aspect of a clinical neurological examination, both as an indicator of a mood disorder and as a sign of neurological damage. To date, although studies have been conducted on certain psychosocial aspects of myasthenia, such as quality of life and anxiety, and on neuropsychological aspects such as memory, no studies have directly assessed facial emotion recognition accuracy. The aim of this study was to assess the facial emotion recognition accuracy (fear, surprise, sadness, happiness, anger, and disgust), empathy, and reaction time of patients with myasthenia. Thirty-five patients with myasthenia and 36 healthy controls were tested for their ability to differentiate emotional facial expressions. Participants were matched with respect to age, gender, and education level. Their ability to differentiate emotional facial expressions was evaluated using the computer-based program Feel Test. The data showed that myasthenic patients scored significantly lower (p < 0.05) than healthy controls in the total Feel score, fear, surprise, and higher reaction time. The findings suggest that the ability to recognize facial affect may be reduced in individuals with myasthenia.

scholarly journals Quantification of human plasma metalloproteins in multiple sclerosis, ischemic stroke and healthy controls reveals an association of haptoglobin-hemoglobin complexes with age

PLoS ONE ◽  
2022 ◽  
Vol 17 (1) ◽  
pp. e0262160
Author(s):  
Sophia Sarpong-Kumankomah ◽  
Katherine B. Knox ◽  
Michael E. Kelly ◽  
Gary Hunter ◽  
Bogdan Popescu ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Ischemic Stroke ◽  
Inductively Coupled Plasma ◽  
Rank Correlation ◽  
Positive Association ◽  
Disease Diagnosis ◽  
Size Exclusion ◽  
Control Group ◽  
Healthy Controls ◽  
Significant Difference

Advanced analytical methods play an important role in quantifying serum disease biomarkers. The problem of separating thousands of proteins can be reduced by analyzing for a ‘sub-proteome’, such as the ‘metalloproteome’, defined as all proteins that contain bound metals. We employed size exclusion chromatography (SEC) coupled to an inductively coupled plasma atomic emission spectrometer (ICP-AES) to analyze plasma from multiple sclerosis (MS) participants (n = 21), acute ischemic stroke (AIS) participants (n = 17) and healthy controls (n = 21) for Fe, Cu and Zn-metalloproteins. Using ANOVA analysis to compare the mean peak areas among the groups revealed no statistically significant differences for ceruloplasmin (p = 0.31), α2macroglobulin (p = 0.51) and transferrin (p = 0.31). However, a statistically significant difference was observed for the haptoglobin-hemoglobin (Hp-Hb) complex (p = 0.04), being driven by the difference between the control group and AIS (p = 0.012), but not with the MS group (p = 0.13), based on Dunnes test. A linear regression model for Hp-Hb complex with the groups now adjusted for age found no statistically significant differences between the groups (p = 0.95), but was suggestive for age (p = 0.057). To measure the strength of association between the Hp-Hb complex and age without possible modifications due to disease, we calculated the Spearman rank correlation in the healthy controls. The latter revealed a positive association (r = 0.39, 95% Confidence Interval = (-0.05, 0.83), which suggests that either the removal of Hp-Hb complexes from the blood circulation slows with age or that the release of Hb from red blood cells increases with age. We also observed that the Fe-peak corresponding to the Hp-Hb complex eluted ~100 s later in ~14% of all study samples, which was not correlated with age or disease diagnosis, but is consistent with the presence of the smaller Hp (1–1) isoform in 15% of the population.

scholarly journals Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Seyedeh Zahra Hosseini Imani ◽  
Zohreh Hojati ◽  
Sheyda Khalilian ◽  
Fariba Dehghanian ◽  
Majid Kheirollahi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Family History ◽  
Area Under The Curve ◽  
Group Versus ◽  
Expression Level ◽  
Inflammatory Factors ◽  
Control Group ◽  
Healthy Controls ◽  
Roc Curve Analysis ◽  
Axonal Dysfunction

AbstractMultiple sclerosis (MS) is a chronic inflammatory and autoimmune disorder of the central nervous system characterized by myelin loss and axonal dysfunction. Increased production of inflammatory factors such as cytokines has been implicated in axon destruction. In the present study, we compared the expression level of IL7R, NFATc2, and RNF213 genes in the peripheral blood of 72 MS patients (37 familial MS, 35 sporadic MS) and 74 healthy controls (34 individuals with a family history of the disease, 40 healthy controls without a family history) via Real-time PCR. Our results showed that the expression level of IL7R was decreased in the sporadic patients in comparison with other groups. Additionally, there was an increased NFATc2 expression level in MS patients versus healthy controls. Increased expression of NFATc2 in sporadic and familial groups compared to the controls, and familial group versus FDR was also seen. Our results also represented an increased expression level of RNF213 in familial patients as compared to the control group. The similar RNF213 expression between sporadic and control group, as well as FDR and familial group was also seen. Diagnostic evaluation was performed by receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) calculation. The correlation of clinical parameters including onset age and Expanded Disability Status Scale (EDSS) with our gene expression levels were also assessed. Overall, decreased expression level of IL7R in the sporadic cases and increased expression level of NFATc2 may be associated with the pathogenesis of MS disease. Confirmation of the effects of differential expression of RNF213 gene requires further studies in the wider statistical populations.

scholarly journals Neuronal correlates of affective theory of mind in schizophrenia out-patients: evidence for a baseline deficit

2010 ◽  
Vol 40 (10) ◽  
pp. 1607-1617 ◽  
Author(s):  
D. Mier ◽  
C. Sauer ◽  
S. Lis ◽  
C. Esslinger ◽  
J. Wilhelm ◽  
...  
Keyword(s):  
Social Cognition ◽  
Theory Of Mind ◽  
Emotion Recognition ◽  
Facial Expressions ◽  
Social Cognitive ◽  
Region Of Interest ◽  
Functional Brain Imaging ◽  
Control Group ◽  
Imaging Data ◽  
Schizophrenia Group

BackgroundSchizophrenia out-patients have deficits in affective theory of mind (ToM) but also on more basal levels of social cognition, such as the processing of neutral and emotional expressions. These deficits are associated with changes in brain activation in the amygdala and the superior temporal sulcus (STS). However, until now there have been no studies that examined these different levels of social cognition and their neurobiological underpinnings in patients within one design.MethodSixteen medicated schizophrenia out-patients and 16 matched healthy controls were studied with functional magnetic resonance imaging (fMRI) during a social cognition task that allows the investigation of affective ToM (aToM), emotion recognition and the processing of neutral facial expressions.ResultsPatients showed a deficit in emotion recognition and a more prominent deficit in aToM. The performance in aToM and in emotion recognition was correlated in the control group but not in the schizophrenia group. Region-of-interest analysis of functional brain imaging data revealed no difference between groups during aToM, but a hyperactivation in the schizophrenia group in the left amygdala and right STS during emotion recognition and the processing of neutral facial expressions.ConclusionsThe results indicate that schizophrenia out-patients have deficits at several levels of social cognition and provide the first evidence that deficits on higher-order social cognitive processes in schizophrenia may be traced back to an aberrant processing of faces per se.

Emotion facial expression in families of patients with schizophrenia

2011 ◽  
Vol 26 (S2) ◽  
pp. 1399-1399
Author(s):  
S. Herrera ◽  
M. Bardón ◽  
C. Fernández ◽  
V. Ángeles ◽  
G. Lahera Forteza ◽  
...  
Keyword(s):  
Mental Health ◽  
Facial Expression ◽  
Healthy Volunteers ◽  
Emotion Recognition ◽  
The Other ◽  
Control Group ◽  
Healthy Controls ◽  
Basic Emotions ◽  
Healthy Control ◽  
Face Emotion Recognition

IntroductionPatients with schizophrenia show a deficit in emotion recognition through facial expression and the low sense of familiarity may be a factor involved. However, the emotion facial expression in families of patients could be disturbed and be another factor related to the deficit in emotion recognition and in sense of familiarity in schizophrenia.ObjectivesTo assess the emotion facial expression in a sample of 21 families of patients with schizophrenia and families of healthy controls.Methods22 healthy volunteers, all of them professionals of mental health, were assessed with the Ekman Test of emotion recognition in unfamiliar people which was photographed by expressing the 6 Ekman’s basic emotions. The task was composed of 42 pictures, half of them from families of patients and the other half from families of healthy control.ResultsVolunteers recognize worse emotions in relatives of patients than in relatives of control group and this difference was statistically significant (Wilcoxon W = -4.13; p = .001). The average of pictures correctly recognized from families of patients was lower than pictures from families of control group (54.28% vs. 82%).ConclusionsThe emotion facial expression in families of patients with schizophrenia seems worse than in families of healthy controls. It could be a factor involved in face emotion recognition deficit in schizophrenia.

scholarly journals The Assessment of Serum Concentrations of AGEs and Their Soluble Receptor (sRAGE) in Multiple Sclerosis Patients

2021 ◽  
Vol 11 (8) ◽  
pp. 1021
Author(s):  
Aleksandra Damasiewicz-Bodzek ◽  
Beata Łabuz-Roszak ◽  
Bartłomiej Kumaszka ◽  
Bartosz Tadeusiak ◽  
Krystyna Tyrpień-Golder
Keyword(s):  
Multiple Sclerosis ◽  
Stable Phase ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Healthy Controls ◽  
Soluble Receptor ◽  
Serum Concentrations ◽  
Degree Of Disability ◽  
The Mean ◽  
Multiple Sclerosis Patients

Background: Advanced glycation end products (AGEs) are involved in the pathogenesis of many diseases, including neurodegenerative diseases such as multiple sclerosis (MS). The aim of the study was to determine serum concentrations of AGEs and their soluble receptor (sRAGE) in MS patients and healthy controls and to investigate their possible influence on disease activity. Methods: Serum concentrations of AGE and sRAGE in patients with MS and healthy controls were determined by enzyme-linked immunosorbent assay (ELISA). Results: The mean serum AGE concentration in patients with MS was higher than in healthy controls, whereas the mean serum sRAGE concentration was lower than in the control group. However, the differences were not statistically significant. In MS patients, serum AGE and sRAGE concentrations did not differ significantly, depending on the duration of the disease and the Expanded Disability Status Scale (EDSS) score. Conclusions: Multiple sclerosis may be accompanied by disturbances of the AGE-sRAGE axis. However, further studies are warranted to confirm it. The duration of the disease and the degree of disability do not seem to affect the progression of the glycation process, particularly in the stable phase of the disease.

Sign in / Sign up

Export Citation Format

Share Document